2-bromo-N-(tert-butyl)-5-((2-(trimethylsilyl)ethoxy)methyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxamide → N-tert-butyl-2-(7-ethyl-1H-indazol-3-yl)-5-((2-(trimethylsilyl)ethoxy)methyl)-5H-pyrrolo[3,2-b]pyrazine-7-carboxamide

HRID 246542

반응식

HRID 246542 반응식
Br[C:2]1[N:7]=[C:6]2[C:8]([C:19]([NH:21][C:22]([CH3:25])([CH3:24])[CH3:23])=[O:20])=[CH:9][N:10]([CH2:11][O:12][CH2:13][CH2:14][Si:15]([CH3:18])([CH3:17])[CH3:16])[C:5]2=[N:4][CH:3]=1.[CH2:26]([C:28]1[CH:29]=[CH:30][CH:31]=[C:32]2[C:36]=1[NH:35][N:34]=[C:33]2I)[CH3:27].C([Sn](CCCC)(CCCC)[Sn](CCCC)(CCCC)CCCC)CCC>CN(C=O)C.C1C=CC([P]([Pd]([P](C2C=CC=CC=2)(C2C=CC=CC=2)C2C=CC=CC=2)([P](C2C=CC=CC=2)(C2C=CC=CC=2)C2C=CC=CC=2)[P](C2C=CC=CC=2)(C2C=CC=CC=2)C2C=CC=CC=2)(C2C=CC=CC=2)C2C=CC=CC=2)=CC=1>[C:22]([NH:21][C:19]([C:8]1[C:6]2=[N:7][C:2]([C:33]3[C:32]4[C:36](=[C:28]([CH2:26][CH3:27])[CH:29]=[CH:30][CH:31]=4)[NH:35][N:34]=3)=[CH:3][N:4]=[C:5]2[N:10]([CH2:11][O:12][CH2:13][CH2:14][Si:15]([CH3:18])([CH3:17])[CH3:16])[CH:9]=1)=[O:20])([CH3:25])([CH3:24])[CH3:23]

참가 물질

6

반응물 3

HCID 715756452-bromo-N-(tert-butyl)-5-((2-(trimethylsilyl)ethoxy)methyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxamideHCID 1784358267-ethyl-3-iodo-1H-indazoleHCID 178448238HCID 178448238, 화합물

생성물 1

HCID 178435669N-tert-butyl-2-(7-ethyl-1H-indazol-3-yl)-5-((2-(trimethylsilyl)ethoxy)methyl)-5H-pyrrolo[3,2-b]pyrazine-7-carboxamide수율 12.2%

시약·촉매·용매 2

HCID 178418397HCID 178418397, 화합물촉매HCID 6228Dimethylformamide용매

반응 조건

온도
115 °C

실험 절차

To a stirred solution of 2-bromo-N-tert-butyl-5-((2-(trimethylsilyl)ethoxy)methyl)-5H-pyrrolo[3,2-b]pyrazine-7-carboxamide (320 mg, 749 μmol) and 7-ethyl-3-iodo-1H-indazole (244 mg, 898 μmol) in DMF (2.5 mL) was added 1,1,1,2,2,2-hexabutyldistannane (651 mg, 412 μL, 1.12 mmol) under N2. After 10 min tetrakis(triphenylphosphine)palladium (0) (43.3 mg, 37.4 mmol) was added and the reaction mixture heated to 115° C. After 16 h the reaction was cooled and concentrated. The residue was diluted with 10% methanol/dichloromethane and filtered through a pad of celite. Purification of the filtrate by chromatography (silica, 5-45% ethyl acetate/hexane) gave N-tert-butyl-2-(7-ethyl-1H-indazol-3-yl)-5-((2-(trimethylsilyl)ethoxy)methyl)-5H-pyrrolo[3,2-b]pyrazine-7-carboxamide (45 mg, 91.3 μmol, 12%) as an off-white solid. MS (M+H)+=493.4; 1H NMR (CDCl3) δ: 10.57 (s, 1H), 9.34 (s, 1H), 8.49 (d, J=7.5, 1H), 8.43 (s, 1H), 8.24 (s, 1H), 7.35 (d, J=7.1 Hz, 1H), 7.29 (t, J=7.1 Hz, 1H), 5.77 (s, 2H), 3.62 (t, J=8.3, 2H), 3.07 (q, J=7.5 Hz, 2H), 1.68 (s, 9H), 1.50 (t, J=7.5 Hz, 3H), 0.98 (t, J=8.3, 2H), 0.0 (s, 9H).

후처리

  1. temperatureAfter 16 h the reaction was cooled
  2. concentrationconcentrated
  3. additionThe residue was diluted with 10% methanol/dichloromethane
  4. filtrationfiltered through a pad of celite
  5. customPurification of the filtrate by chromatography (silica, 5-45% ethyl acetate/hexane)

출처 및 근거

ORD 기록
ord-37e353dc89ba49db88c78dca5010d225
출처 데이터셋
uspto-grants-2014_02
특허 번호
US08658646B2

연결된 노트

불러오는 중…